A
Anna Vassall
Researcher at University of London
Publications - 189
Citations - 4937
Anna Vassall is an academic researcher from University of London. The author has contributed to research in topics: Cost effectiveness & Medicine. The author has an hindex of 34, co-authored 157 publications receiving 3838 citations. Previous affiliations of Anna Vassall include University of Amsterdam & Royal Tropical Institute.
Papers
More filters
Journal ArticleDOI
Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
Anna Vassall,Sanne van Kampen,Hojoon Sohn,Joy Sarojini Michael,K. R. John,Saskia den Boon,J. Lucian Davis,Andrew Whitelaw,Andrew Whitelaw,Mark P. Nicol,Mark P. Nicol,Maria Tarcela Gler,Anar Khaliqov,Carlos Zamudio,Mark D. Perkins,Catharina Boehme,Frank Cobelens +16 more
TL;DR: A cost-effectiveness study reveals that Xpert MTB/RIF is a cost-effective method of tuberculosis diagnosis that is suitable for use in low- and middle-income settings.
Journal ArticleDOI
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Michael J. A. Reid,Nimalan Arinaminpathy,Amy Bloom,Barry R. Bloom,Catharina Boehme,Richard E. Chaisson,Daniel P. Chin,Gavin J. Churchyard,Helen Cox,Lucica Ditiu,Mark Dybul,Jeremy Farrar,Anthony S. Fauci,Endalkachew Fekadu,Paula I Fujiwara,Timothy B. Hallett,Christy L Hanson,Mark Harrington,Nick Herbert,Philip C. Hopewell,Chieko Ikeda,Dean T. Jamison,Aamir J. Khan,Irene Koek,Nalini Krishnan,Aaron Motsoaledi,Madhukar Pai,Mario C. Raviglione,Mario C. Raviglione,Almaz Sharman,Small Pm,Soumya Swaminathan,Zelalem Temesgen,Anna Vassall,Anna Vassall,Nandita. Venkatesan,Kitty van Weezenbeek,Gavin Yamey,Bruce D. Agins,Sofia Alexandru,Jason R. Andrews,Naomi Beyeler,Stela Bivol,Grania Brigden,Adithya Cattamanchi,Danielle Cazabon,Valeriu Crudu,Amrita Daftary,Puneet Dewan,Laurie K Doepel,Robert W Eisinger,Victoria Y. Fan,Victoria Y. Fan,Sara Fewer,Jennifer Furin,Jeremy D. Goldhaber-Fiebert,Gabriela B. Gomez,Stephen M. Graham,Stephen M. Graham,Stephen M. Graham,Devesh Gupta,Maureen Kamene,Sunil D. Khaparde,Eunice W Mailu,Enos Masini,Lorrie McHugh,Ellen M. H. Mitchell,Suerie Moon,Suerie Moon,Michael Osberg,Tripti Pande,Lea Prince,Kirankumar Rade,Raghuram Rao,Michelle Remme,James A Seddon,James A Seddon,Casey Selwyn,Priya B. Shete,Kuldeep Singh Sachdeva,Guy Stallworthy,Juan F. Vesga,Valentina Vilc,Eric Goosby +83 more
TL;DR: The Commission recommends five priority investments to achieve a tuberculosis-free world within a generation, which answer the question of how countries with high-burden tuberculosis and their development partners should target their future investments.
Journal ArticleDOI
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
Gabriela B. Gomez,Annick Borquez,Kelsey K. Case,Ana Wheelock,Anna Vassall,Catherine Hankins,Catherine Hankins +6 more
TL;DR: Gabriela Gomez and colleagues systematically review cost-effectiveness modeling studies of pre-exposure prophylaxis for preventing HIV transmission and identify the main considerations to address when considering the introduction of PrEP to HIV prevention programs.
Journal ArticleDOI
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF
Gavin J. Churchyard,Gavin J. Churchyard,Wendy S. Stevens,Wendy S. Stevens,Lerole D Mametja,Kerrigan McCarthy,Violet N. Chihota,Mark P. Nicol,Mark P. Nicol,Linda Erasmus,Norbert Ndjeka,L Mvusi,Anna Vassall,Edina Sinanovic,Helen Cox,Christopher Dye,Alison D. Grant,Alison D. Grant,Katherine Fielding +18 more
TL;DR: Xpert did not reduce mortality at 6 months compared with sputum microscopy, and improving outcomes in drug-sensitive tuberculosis programmes might require not only better diagnostic tests but also better linkage to care.
Journal ArticleDOI
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
Gwenan M. Knight,Ulla K. Griffiths,Tom Sumner,Yoko V. Laurence,Adrian Gheorghe,Anna Vassall,Philippe Glaziou,Richard G. White +7 more
TL;DR: It is suggested that to achieve the 2050 elimination goals, future TB vaccine development should focus on vaccines targeted at adolescents/adults, even if only relatively low efficacies and short durations of protection are technically feasible.